Zhengye Biotechnology revenue declines 18.3% in first half of 2026 as customers cut costs
ZYBT•Zhengye Biotechnology’s first-half 2026 revenue fell 18.3% to RMB 50.95 million as customers cut costs, while its net loss narrowed to RMB 22.16 million.
1. Revenue and costs
Revenue fell 18.3% to RMB 50.95 million as customers’ sustained losses and cost-cutting reduced sales volumes, management said. Sales to the company’s previously largest customer fell to RMB 5.2 million from RMB 12.5 million after it began producing vaccines internally.
2. Loss and cash flow
The net loss narrowed to RMB 22.16 million, reflecting lower operating expenses, which fell to RMB 37.57 million. Operating cash outflow widened to RMB 16.81 million as uncollected receivables and inventory buildup weighed on working capital, management said.
